Intrarosa uk patent?

What is the “Intrarosa” UK patent people are searching for?

“Intrarosa” is the brand name for prasterone (also called DHEA) used for genitourinary symptoms associated with menopause. When people search “Intrarosa UK patent,” they usually mean one of the UK intellectual property rights that protect the product or its regulatory exclusivity in the UK after approval—most often a patent or a supplementary protection mechanism tied to the active ingredient and/or the medicinal use.

Which UK rights typically protect Intrarosa (patent vs. SPC)?

In the UK, protection around a prescription medicine can come from different layers:
- A standard patent (covering an invention such as a formulation, method of treatment, or composition).
- An SPC (supplementary protection certificate), which extends market exclusivity in certain cases based on the first marketing authorization in a country.
- Other rights (for example, regulatory exclusivity mechanisms that can run alongside patent/SPC protection).

The exact “Intrarosa UK patent” depends on what the searcher wants (original composition, a specific method of use, or the exclusivity extension).

How can you find the exact Intrarosa patent number in the UK?

The quickest way to get the specific UK patent(s) is to look up:
- The UK Intellectual Property Office (UKIPO) register for patents and any associated supplementary protection certificates (SPCs).
- The SPC register entries that are tied to the product and active ingredient.

If you share the patent number you’re seeing (or the claim wording / applicant name / UK marketing authorization holder), I can help interpret what that specific UK right covers.

When does Intrarosa patent/SPC protection end in the UK?

End dates depend on which right you mean (the earliest priority date, SPC duration rules, and any later patents in the UK). For “Intrarosa uk patent” searches, people are often trying to estimate when generics or competing products could enter.

To answer accurately, you need the specific patent/SPC entry you’re looking at (the register entry includes the relevant end date).

Can generic or competing prasterone products enter the UK before the latest Intrarosa patent expires?

Potential timing depends on:
- Whether the competitor has to wait out patent/SPC barriers for the relevant claims.
- Whether a product can launch under any legal “skinny label” or other regulatory/patent strategy that avoids infringement (this depends on what’s claimed in the active UK rights).
- The status of any UK litigation or challenges to the validity of the patents/SPCs.

Without the exact UK patent/SPC number(s), it isn’t possible to state whether entry could happen now or only after a particular date.

What should you check if you’re trying to assess infringement or “freedom to operate”?

For a “freedom to operate” view in the UK, the key fields are:
- The specific UK patent claims that are in force.
- Whether an SPC exists and what it covers.
- The expiration date of that specific right (not just the original patent).
- The competitor’s product particulars (active ingredient, dose form, and how it’s positioned/indicated).

If you paste the UK patent/SPC number (or a link/screenshot text from the UKIPO entry), I can map it to what it likely covers and what it means practically for competitors.

---

Sources

I can’t cite specific “Intrarosa UK patent” entries because no patent/SPC number or register link was provided. If you send the patent/SPC number (or the UKIPO entry link), I’ll use it to give a precise answer with dates and scope.